Shares of Cepheid hit a 52-week high of $20.29 on Tuesday before closing at $20.17. The stock led all gainers in the BCW Index for the three-week period ended Tuesday, up 19.4 percent (BioCommerce Week did not publish the past two weeks and the last Index ran on Aug. 15). Cepheid signed an anthrax test agreement with the US Postal Service in mid-August worth a potential $200 million to the firm (see Briefs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.